<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01797718</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT:2012-002477-59</org_study_id>
    <nct_id>NCT01797718</nct_id>
  </id_info>
  <brief_title>Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment</brief_title>
  <acronym>CDGP</acronym>
  <official_title>Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation for Paediatric Research, Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Boys with constitutional delay of growth and puberty (CDGP) should be offered evidence-based
      effective and safe treatment option. This study compares the effects of low-dose testosterone
      and aromatase inhibitor letrozole on pubertal progression. The hypothesis is that, in boys
      CDGP showing earliest signs of puberty, peroral letrozole (2.5 mg/d for 6 mo) induces faster
      biochemical and clinical progression of puberty as compared to low-dose intramuscular
      testosterone Rx (~1mg/kg/mo for 6 mo). In addition, 10 or more boys who select watchful
      waiting instead of medication will provide background data on the natural progression of
      CDGP, and their data will not be used in primary statistical comparisons.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2013</start_date>
  <completion_date type="Actual">February 5, 2018</completion_date>
  <primary_completion_date type="Actual">March 20, 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>testicular volume</measure>
    <time_frame>one year</time_frame>
    <description>Testes will be measured with a ruler to the nearest millimeter and volume will be calculated at 0, 6, and 12 mo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical and biochemical measures of pubertal progression</measure>
    <time_frame>one year</time_frame>
    <description>Activity of the hypothalamic-pituitary-gonadal axis, evaluated by
genital and pubic hair stage of puberty according to Tanner;
growth velocity (cm/yr);
basal and gonadotropin-releasing hormone (GnRH)-stimulated gonadotropin levels;
urinary luteinizing hormone levels;
testosterone;
inhibin B;
anti-mullerian hormone (AMH)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone health</measure>
    <time_frame>one year</time_frame>
    <description>Several endpoints related to bone health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychosocial well-being</measure>
    <time_frame>one year</time_frame>
    <description>Psycho-social well-being will assessed with questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Puberty-related metabolical and clinical changes</measure>
    <time_frame>one year</time_frame>
    <description>Biochemical and metabolical changes will be compared btw testosterone and letrozole treatment groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Constitutional Delay of Growth and Puberty</condition>
  <arm_group>
    <arm_group_label>Testosterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>~1mg/kg every 4 weeks for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.5mg daily for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>1mg/kg every 4 weeks for 6 months</description>
    <arm_group_label>Testosterone</arm_group_label>
    <other_name>Sustanon 250</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>2.5mg daily for 6 months. Safety criteria: if testosterone level is above 30nM at 3 months, the dosage is reduced to 2.5mg every other day</description>
    <arm_group_label>Letrozole</arm_group_label>
    <other_name>Letrozole Bluefish</other_name>
    <other_name>Letrozole Orion</other_name>
    <other_name>Letrozole Accord</other_name>
    <other_name>Letrozole Sandoz</other_name>
    <other_name>Femar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Constitutional delay of growth and puberty

          -  Age 14 years or more

          -  mean testicular volume 2.5 ml or more and less than 4 ml

          -  serum testosterone level less than 5 nM OR

        as above, but serum testosterone 1 nM or more with normal DHEAS level, even if the mean
        testicular volume is less than 2.5 ml OR

        as above, but tanner stage G2 and testosterone level less than 3 nM

        Exclusion Criteria:

          -  Chronic diseases

          -  Primary or secondary hypogonadism

          -  Chromosomal anomalies

          -  Chronic medication that potentially adversely affects bone mineralization (excluding
             inhaled corticosteroid treatment)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taneli Raivio, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matti Hero, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tero Varimo, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>PÃ¤ivi Miettinen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorma Toppari, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Turku</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hanna Huopio, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Kuopio University Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sirpa Tenhola, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Kymeenlaakso Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raimo Voutilainen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Kuopio University Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kotka Central Hospital</name>
      <address>
        <city>Kotka</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuopio University Central Hospital</name>
      <address>
        <city>Kuopio</city>
        <zip>70211</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku University Central Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2013</study_first_submitted>
  <study_first_submitted_qc>February 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2013</study_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Tero Varimo, MD, PhD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Puberty</keyword>
  <keyword>Constitutional</keyword>
  <keyword>Delay</keyword>
  <keyword>Letrozole</keyword>
  <keyword>Testosterone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

